Receive regular headline summaries whenever high-quality news is generated for Healthcare Cost Comparison. We'll never share your email address with others.
|Shares Healthcare News With (link):|
|Other Healthcare Entities||We are still establishing shared news links for this healthcare topic.|
|Date||Headline (link)||Source||Relevant Snippet|
|7/3/2019||Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma||biomedcentral.com||Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant breakthroughs in the treatment of advanced melanoma. A combination of the 2 agents has demonstrated efficacy and survival benefits over NIVO or IPI monotherapy in treating advanced melanoma. We compared melanoma-specific costs following treatment with NIVO + IPI, NIVO monotherapy, or IPI monotherapy ...|